Annual Drug Patent Expirations for ORILISSA
Orilissa is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug.
Drug patent litigation for ORILISSA.
This drug has ninety-seven patent family members in twenty-six countries.
The generic ingredient in ORILISSA is elagolix sodium. One supplier is listed for this compound. Additional details are available on the elagolix sodium profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
